Evaluation of Topical Glyceryl Trinitrate on Genitourinary Syndrome of Menopause and Female Sexual Dysfunction in Peri- and Postmenopausal Women: A Pilot Study

The primary objective of this study is to evaluate the effect of **topical glyceryl trinitrate** on female genital function in individuals experiencing **Genitourinary Syndrome of Menopause** during the peri- and postmenopausal phases. This condition is characterized by a range of symptoms affecting the genitourinary tract, which can significantly impact quality of life and sexual function. Understanding the efficacy of glyceryl trinitrate in alleviating these symptoms is clinically relevant as it may offer a therapeutic option for improving sexual health and overall well-being in affected women.

The clinical trial focuses on participants diagnosed with **Genitourinary Syndrome of Menopause**. The study population comprises exclusively female subjects, with an age range that includes middle-aged to older adults. The trial does not include male participants. The sponsor has not provided the total number of participants involved in the study. The selection process for the trial population is not detailed, but it is noted that a vulnerable population is included. Specific lifestyle considerations such as diet, physical activity, or habits are not mentioned. The sponsor has not disclosed key inclusion or exclusion criteria for this trial.

The clinical trial is designed to evaluate the effect of topical glyceryl trinitrate on female genital function in individuals experiencing **Genitourinary Syndrome of Menopause**. This study is structured as a Phase 3, randomized, double-blind, controlled trial, ensuring that neither the participants nor the researchers know who is receiving the treatment or placebo, thereby minimizing bias. The trial is set to commence recruitment on February 10, 2025, and is expected to conclude by December 31, 2027, providing a comprehensive evaluation period.

Participants will undergo a series of study visits, beginning with an inclusion visit, which serves as a screening to determine eligibility based on predefined criteria. This visit will involve a thorough assessment to ensure participants meet the necessary conditions for inclusion. Following the initial screening, participants will attend regular follow-up visits, which are crucial for monitoring the effects of the treatment, assessing any adverse events, and ensuring adherence to the study protocol. The sequence and frequency of these visits will be determined by the study protocol to ensure consistent data collection and participant safety. The trial will culminate in an end-of-study visit, where final assessments will be conducted to evaluate the primary and secondary endpoints of the study.

The expected duration of participant involvement will span the entire trial period, from the initial screening to the end-of-study visit, unless specific conditions necessitate early termination. Such conditions may include adverse reactions to the treatment, non-compliance with the study protocol, or withdrawal of consent by the participant. The trial's design and procedures are meticulously crafted to ensure the collection of reliable data while prioritizing participant safety and well-being throughout the study duration.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the **experimental medication**, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the absence of specific details, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be included. The data does not contain any information about the **disease** being studied, the trial's main objective, or any other pertinent details that would typically be included in a clinical trial description.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on February 10, 2025, with an estimated completion date of December 31, 2027. The efficacy assessment will be conducted using predefined primary and secondary endpoints, although specific endpoints are not detailed in the available data. The trial will follow a structured methodology to ensure the accurate measurement and analysis of efficacy parameters. The trial's design and execution will adhere to rigorous standards to ensure the reliability and validity of the efficacy outcomes.